Fate Therapeutics (FATE) Depreciation & Amortization (CF) (2012 - 2026)

Fate Therapeutics (FATE) has 15 years of Depreciation & Amortization (CF) data on file, last reported at $2.9 million in Q1 2026.

• Quarterly Depreciation & Amortization (CF) fell 12.45% year-over-year to $2.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.5 million (down 28.55% YoY) and the FY2025 annual result came in at $12.9 million, down 31.96% from the prior year.
• Depreciation & Amortization (CF) fell to $2.9 million in Q1 2026, from $3.1 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $4.9 million in Q4 2023 to a low of $2.8 million in Q1 2022.
• A 5-year average of $3.9 million and a median of $4.2 million in 2023 frame the typical range for Depreciation & Amortization (CF).
• Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) soared 187.9% — and 2025, when it sank 36.36%.
• Tracing FATE's Depreciation & Amortization (CF) over 5 years: stood at $4.9 million in 2022, then climbed by 0.02% to $4.9 million in 2023, then declined by 1.47% to $4.8 million in 2024, then tumbled by 36.36% to $3.1 million in 2025, then dropped by 4.73% to $2.9 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $2.9 million (Q1 2026), $3.1 million (Q4 2025), and $3.2 million (Q3 2025), per Business Quant data.